SAMSUNG BIOLOGICS CO.,LTD. (207940) · Disclosure ·
[Amended]
Other filing (Korean only)
Original title: [발행조건확정]증권신고서(지분증권)
English summary pending. The original filing is linked below.
Receipt no. 20261105000415
More filings from SAMSUNG BIOLOGICS CO.,LTD.
Other filing (Korean only)
Original title: [기재정정]주요사항보고서(타법인주식및출자증권양수결정)
Other filing (Korean only)
Original title: [기재정정]타법인주식및출자증권취득결정(종속회사의주요경영사항)
Other filing (Korean only)
Original title: [기재정정]투자설명서
Other filing (Korean only)
Original title: 유상증자신주발행가액(안내공시)
[Amended] SAMSUNG BIOLOGICS CO.,LTD. to raise equity via a rights issue followed by a public offering of unsubscribed shares
SAMSUNG BIOLOGICS CO.,LTD. disclosed a board resolution dated 2026-08-28 to raise new equity through a rights issue followed by a public offering of unsubscribed shares, issuing 2,270,000 shares of new common stock at a preliminary KRW 1.17 million per share, for total proceeds of about KRW 2.66 trillion. The new shares represent 4.9% of the 46,290,951 shares outstanding before the offering, and the proceeds are earmarked for the acquisition of other companies' securities. Subscription runs from 2026-11-09 to 2026-11-10, with payment due on 2026-11-17 and listing scheduled for 2026-11-30. Any shares left unsubscribed will be offered to the general public from 2026-11-12 to 2026-11-13, and the issue price will be finalised shortly before subscription begins.
Source data: DART (Data Analysis, Retrieval and Transfer System), Financial Supervisory Service of Korea — original filing.